Gilead unexpectedly cashes in with nearly $900 million in sales of COVID-19 drug

Gilead Sciences Inc.’s prominent COVID-19 drug unexpectedly brought in $100 more million in sales than analysts had expected in the third quarter, but that doesn’t mean Wall Street’s questions about Veklury have faded away.

from MarketWatch.com - Top Stories https://ift.tt/2TxelpY
via IFTTT

Kommentare

Beliebte Posts aus diesem Blog

Kelley Blue Book: What is the Mercedes-Benz EQB?

This is the German automaker's all-electric version of the popular compact GLB SUV. from MarketWatch.com - Top Stories https://ift.tt/3zuLGnP via IFTTT

Tax Loophole Found for Home-Equity Loan Interest

Homeowners may still qualify for a tax break on their home-equity loan interest thanks to a loophole in the recent Tax Cuts and Jobs Act. from rss_headline https://ift.tt/2SZ3e6R via IFTTT

MarketWatch First Take: Big Tech painted as the railroad barons of the digital age in antitrust hearing

For the most part — if you could tune out the political grandstanding that had nothing to do with antirust — the Congressional hearing on Big Tech gave many pointed examples of how four of the biggest tech companies in the U.S. abuse their dominant power and thwart competition. from MarketWatch.com - Top Stories https://ift.tt/2XbPKcx via IFTTT

Finance

Dieses Blog durchsuchen